Skip to main content

Gonadorelin

Source index · checked quotations available

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

Hormones21 cited mentions
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Gonadorelin; the papers are listed at the end. Research summary, not a recommendation.

What it is

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH, also called LHRH), a natural decapeptide of 10 amino acids made by a small group of nerve cells in the hypothalamus. Its structure was worked out in 1971 by the groups of Andrew Schally and Roger Guillemin, who shared the 1977 Nobel Prize for the discovery. Gonadorelin has the same sequence as the natural hormone, which distinguishes it from the modified long-acting GnRH analogues (leuprolide, triptorelin and others) used to suppress sex hormones. It has been an FDA-approved product for diagnostic testing of pituitary function (Factrel) and, as a pump-delivered form (Lutrepulse), for inducing ovulation; both human products were later withdrawn from the US market for commercial reasons, and gonadorelin remains an approved veterinary drug for cattle. In the United States it is now obtained from compounding pharmacies.

How it works

GnRH is released from the hypothalamus in pulses, roughly every one to two hours, and travels through a short portal blood system to the pituitary, where it binds the GnRH receptor on gonadotroph cells. Each pulse triggers release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which act on the testes to drive testosterone production and sperm formation and on the ovaries to drive follicle growth, estrogen production and ovulation. The pattern matters more than the amount: pulsed GnRH stimulates the axis, whereas continuous exposure desensitizes the receptor and shuts LH and FSH off, which is how the long-acting analogues suppress sex hormones. Gonadorelin is cleared from the blood within minutes, so for stimulation it is given as a single diagnostic injection or by a programmable pump that mimics the natural pulses.

What it has been studied for

  • Diagnostic testing of pituitary gonadotropin reserve (the original clinical studies)
  • Ovulation induction by pulsatile GnRH in women with hypothalamic amenorrhea and polycystic ovary syndrome (Cochrane review and controlled studies)
  • Induction of puberty, testosterone production and sperm formation in men with congenital hypogonadotropic hypogonadism (comparative human studies)
  • Men who did not respond to gonadotropin injections (human case series)
  • Physiology of the GnRH neuron and pulse generator (reviews)

Strength of the evidence

Approved drugGonadorelin has held FDA approval for diagnostic testing and for pulsatile ovulation induction, and pulsatile GnRH is an established treatment for hypogonadotropic hypogonadism in the endocrine literature; the human products are no longer marketed in the United States, and its popular use alongside testosterone therapy to maintain testicular function has not been tested in a published controlled trial.

What the literature reports on safety

In the diagnostic and pump studies gonadorelin was reported as well tolerated, with injection-site reactions, headache, flushing and nausea the most common effects and rare allergic reactions including anaphylaxis described in the labels. Pulsatile use in women carries a risk of multiple pregnancy and, less often than with gonadotropin injections, ovarian hyperstimulation. The approved human products (Factrel and Lutrepulse) were discontinued in the United States, so current use relies on compounded gonadorelin; it is prohibited in sport by the World Anti-Doping Agency for male athletes as a hormone that raises testosterone.

Key papers

  1. Control of puberty onset and fertility by gonadotropin-releasing hormone neurons (opens in a new tab)

    Review · Herbison AE · Nature Reviews Endocrinology (2016) · PMID 27199290

    Reviewed how the hypothalamic GnRH neurons generate pulses and surges and how kisspeptin neurons control them to time puberty and ovulation.

  2. Clinical Management of Congenital Hypogonadotropic Hypogonadism (opens in a new tab)

    Review · Young J, Xu C, et al. · Endocrine Reviews (2019) · PMID 30698671

    Set out the diagnosis and treatment of GnRH deficiency, including pulsatile GnRH and gonadotropin injections as the two ways to restore fertility.

  3. Hormonal control of spermatogenesis in men: therapeutic aspects in hypogonadotropic hypogonadism (opens in a new tab)

    Review · Pitteloud N, Dwyer A · Annales d'Endocrinologie (2014) · PMID 24793994

    Reviewed the hormonal requirements for sperm production and the outcomes of pulsatile GnRH and gonadotropin therapy in men with GnRH deficiency.

  4. Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome (opens in a new tab)

    Review · Bayram N, van Wely M, et al. · Cochrane Database of Systematic Reviews (2004) · PMID 14973957

    A Cochrane review that found pulsatile GnRH induced ovulation in women with polycystic ovary syndrome but that the randomized evidence on pregnancy rates was too small to draw firm conclusions.

  5. The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men (opens in a new tab)

    Cohort study · Zhang L, Cai K, et al. · American Journal of Men's Health (2019) · PMID 30569789

    In men with congenital GnRH deficiency a pulsatile gonadorelin pump produced sperm in the ejaculate sooner than gonadotropin injections, with similar eventual success.

  6. Pulsatile gonadotropin releasing hormone therapy for spermatogenesis in congenital hypogonadotropic hypogonadism patients who had poor response to combined gonadotropin therapy (opens in a new tab)

    Case series · Huang Z, Wang X, et al. · Archives of Endocrinology and Metabolism (2024) · PMID 38739523

    Reported that pulsatile GnRH induced sperm production in a share of men who had failed to respond to gonadotropin injections.

  7. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones (opens in a new tab)

    Animal study · Schally AV, Arimura A, et al. · Science (1971) · PMID 4938639

    The discovery paper showing that a single hypothalamic decapeptide released both LH and FSH, the basis for gonadorelin's synthesis and clinical use.

  8. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence (opens in a new tab)

    Lab (in vitro) · Matsuo H, Baba Y, et al. · Biochemical and Biophysical Research Communications (1971) · PMID 4936338

    Reported the 10-amino-acid sequence of GnRH, which is the sequence of gonadorelin.

Sources checked: PubMed/PMC (E-utilities esummary on every PMID), written 2026-11-06.

Hunter Williams, in his own words

Figures quoted, not recommended. These are Hunter Williams' descriptions, not an agreed treatment protocol.

5 quotations from his library pages, each with its source. A quote marked with a product name is about a blend that includes Gonadorelin.

What he says it is for

His stated dose, protocol and cycle

Cautions he raises

Figures quoted from the practitioner named. We cite, we do not recommend.

Hunter Williams

→ profile

Protocol systematizer

Ask the Gonadorelin Librarian

Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.

What have the teachers said about Gonadorelin? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.

AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Gonadorelin — Hunter, Taylor, Bachmeyer | Reset Biology